Emma Bloch

Emma Bloch

Auto-generated profile, based on publicly available information

Emma Bloch

Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université de Paris, Paris, France

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
EBEmma Bloch
Emma Bloch
GBGaëlle Baudemont
Gaëlle Baudemont
FDFrançoise Donnadieu
Françoise Donnadieu
LGLaura Garcia
Laura Garcia
SPStephane Pelleau
Stephane Pelleau
MWMichael White
Michael White
Background Vaccine-preventable diseases and common viral infections pose substantial public health challenges worldwide. Applying multiplex serological assays to samples collected from cross-sectional studies allows assessment of population-level immunity to a broad range of pathogens. Methods We develop a high-throughput multiplex serological assay using bead-based Luminex technology to measure IgG antibody responses to a broad panel of pathogens. Vaccine preventable diseases include pertussis, diphtheria, tetanus, measles, mumps, and rubella. Common viral infections include adenovirus, cytomegalovirus, Epstein-Barr virus, chickenpox, respiratory syncytial virus, echovirus, Coxsackie B virus, rhinovirus, norovirus, rotavirus, influenza A, hepatitis A, hepatitis E, and the seasonal coronaviruses 229E, OC43, NL63, and HKU1. Measured antibody responses are analysed with statistical models to assess seroprevalence within the French population. Results The analysis of 2132 serum samples from French children and adults reveals notable variation in seroprevalence among different age groups. Consistently high seroprevalence for endemic viruses is observed across all age groups, suggesting widespread exposure from a young age and continuous exposure throughout life. Similarly, mandatory vaccine seroprevalence remains consistently high, reflecting a strong vaccination coverage in France. Conclusions These findings highlight the potential of high-throughput multiplex serology assays for routine surveillance of common viral infections and assessment of vaccine coverage.

27 April 2024 in medRxiv
Verified
Preprint
Open access
PDF file
EBEmma Bloch
Emma Bloch
GBGaëlle Baudemont
Gaëlle Baudemont
FDFrançoise Donnadieu
Françoise Donnadieu
LGLaura Garcia
Laura Garcia
SPStephane Pelleau
Stephane Pelleau
MWMichael White
Michael White
Vaccine-preventable diseases (VPDs) and common viral infections (CVIs) pose substantial public health challenges. Despite data collected through routine vaccination programs and through hospital-based case reporting systems, the understanding of population-level immunity to VPDs and CVIs remains limited. To address this challenge, this study focuses on the development and application of a high-throughput multiplex serological assay to assess IgG levels against a large panel of eight VPDs (e.g., tetanus, diphtheria, measles, mumps, rubella) and 18 CVIs that typically occur in early childhood (e.g., adenovirus, cytomegalovirus, respiratory syncytial virus). A cross-sectional study of 2,032 serum samples from French children and adults was used to optimize and validate a 47-plex assay. These antibody measurements allowed us to enhance our understanding of immunity, vaccination and booster dose effect, as well as antibody waning over time. Preliminary results demonstrate the importance of age-stratified IgG level measurements, revealing notable variation in seroprevalence patterns among different age groups. These findings suggest that there are variations in immunity and exposure to the targeted pathogens across these groups. These findings highlight the potential of high-throughput multiplex serology assays for routine surveillance of common viral infections and assessment of vaccine coverage.

27 October 2024 in medRxiv
Verified
Preprint
Open access
PDF file
EBEmma Bloch
Emma Bloch
LGLaura Garcia
Laura Garcia
FDFrançoise Donnadieu
Françoise Donnadieu
JRJason Rosado
Jason Rosado
DPDelphine Planas
Delphine Planas
MWMichael White
Michael White
SARS-CoV-2 remains a significant health threat due to its high infection and mutation rates. The emergence of new variants of concern poses challenges as they can lead to immune escape mutations, potentially reducing the efficacy of vaccines and antibody therapeutics. The receptor binding domain (RBD) of SARS-CoV-2 is particularly noteworthy as it is both the most rapidly evolving domain and the principal target of neutralizing antibodies. As an alternative to time-consuming and expensive neutralization assays, we have developed a bead-based multiplex surrogate virus neutralization test based on ACE2-RBD binding inhibition. We demonstrated how our high-throughput assay allows us to simultaneously assess anti-RBD neutralizing antibodies levels against multiple SARS-CoV-2 variants, providing data that is consistent with the gold-standard live virus neutralization assay. The utility of this assay was demonstrated by applying it to a large French population cohort to demonstrate that hybrid immunity (generated by a combination of vaccination and infection) is associated with protection against infection with the Omicron BA.1 and BA.2 lineages of SARS-COV-2.

22 May 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
AJAnthony Jaquaniello
Anthony Jaquaniello
FDFlorian Dubois
Florian Dubois
FRFarah Rahal
Farah Rahal
TDTom Dott
Tom Dott
SCSlobodan Culina
Slobodan Culina
DDDarragh Duffy
Darragh Duffy
Human immune responses vary across individuals due to both genetic and environmental factors. We previously established the Milieu Intérieur cohort to define boundaries of healthy immune variation and identify their determinants. To evaluate how immune responses change over time and test whether immune states can predict future disease, we conducted a 10-year follow-up of the cohort. Here we show widespread changes in humoral responses to pathogens over this period, including unexpected seroreversion of cytomegalovirus (CMV) status, despite a general age-related increase in CMV antibodies. We also investigated whether immune profiles at initial recruitment are associated with disease development a decade later. Strikingly, whole blood transcriptional responses to Staphylococcus aureus and Candida albicans stimulation were predictive of subsequent infectious disease. Collectively, the Milieu Intérieur longitudinal study represents a valuable resource for evaluating immune aging and may help identify predictors of adverse health outcomes.

5 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
EBEmma Bloch
Emma Bloch
FDFiona Devys
Fiona Devys
FCFabien Cannac
Fabien Cannac
MJMonika Jain
Monika Jain
KBKatrina Broadbent
Katrina Broadbent
LMLuis M. Molinos-Albert
Luis M. Molinos-Albert
Malaria is a leading cause of childhood mortality, yet infant immune responses to vaccination remain poorly understood. Here, we characterize 88 monoclonal antibodies (mAbs) directed against the Plasmodium falciparum circumsporozoite protein cloned from African infants immunized with the RTS,S/AS01 E malaria vaccine, identifying potent antiparasitic mAbs exhibiting molecular features resembling those observed in adults and minimal somatic hypermutation. Importantly, germline-reverted variants of four mAbs inducing sterile protection in vivo maintained high binding affinity and Fab-dependent parasite killing. Structural analyses revealed that a few amino acid replacements drive homotypic helical assemblies, fine-tuning parasite inhibition and protective efficacy. Thus, despite maturational constraints of early life, infants can generate potent antimalarial antibodies in a near-germline configuration, informing next-generation vaccine development for this vulnerable group.